Requirements Office Based Opioid Treatment (OBOT) Providers

Requirements Office Based Opioid Treatment (OBOT) Providers A. Office Based Opioid Treatment (OBOT) Services must meet the following requirements: 1. Individualized, patient-centered assessment and treatment. 2. Assessing, ordering, administering, reassessing, and regulating medication and dose levels appropriate to the person; supervising withdrawal management from opioid analgesics; overseeing and facilitating access to appropriate treatment for OUD and other substance use disorders (SUD). 3. Buprenorphine mono product shall only be prescribed to pregnant women. 4. Maximum daily buprenorphine/naloxone dose of 16 mg unless there is documentation of an ongoing compelling clinical rationale for a higher maintenance dose up to maximum of 24 mg. 5. Programs should require all persons to be benzodiazepine free after 90 days of admission unless strict monitoring is taking place by a licensed professional and treatment team. 6. Medication for other physical and mental health disorders is provided as needed either on-site or through collaboration with or referral to other providers. 7. Cognitive, behavioral, and other SUD-focused therapies, reflecting a variety of treatment approaches, provided to the patient on an individual, group, and/or family basis. 8. Care coordination provided including interdisciplinary care planning between buprenorphine-waivered practitioner and the licensed behavioral health provider to develop and monitor individualized and personalized treatment plans that are focused on the best outcomes for the patient, monitoring patient progress and tracking patient outcomes, linking patients with community resources (including recovery support services) to facilitate referrals and respond to social service needs, and tracking and supporting patients when they obtain medical, behavioral health, or social services outside the practice. 9. Provision of or referral for screening for HIV, Hepatitis B and C, and Tuberculosis (TB) at treatment initiation and then annually. Risk management and adherence monitoring if they test positive. 10. Routine and/or random urine drug screens conducted a minimum of eight (8) times per year for all patients with at least some tests unannounced or random. 11. Mississippi Prescription Monitoring Program checked at least quarterly for all patients. 12. Opioid overdose prevention education including the prescribing of naloxone for all patients. 13. Patients seen at least weekly during the first month when initiating treatment. Patient must have been seen for at least three (3) months with documented clinical stability before spacing out to a minimum of monthly visits with buprenorphine-waivered practitioner or licensed behavioral health provider. 14. Periodic monitoring of unused medication and opened medication wrapper counts when clinically indicated.